Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
385.65
+10.67 (2.85%)
At close: Aug 6, 2025, 4:00 PM
386.00
+0.35 (0.09%)
After-hours: Aug 6, 2025, 7:58 PM EDT
Smartsheet Revenue
Vertex Pharmaceuticals had revenue of $2.96B in the quarter ending June 30, 2025, with 12.06% growth. This brings the company's revenue in the last twelve months to $11.42B, up 10.46% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.42B
Revenue Growth
+10.46%
P/S Ratio
8.69
Revenue / Employee
$1,871,934
Employees
6,100
Market Cap
98.88B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Novo Nordisk | 49.11B |
Eli Lilly and Company | 49.00B |
VRTX News
- 1 day ago - Weakness In Vertex Stock Seen As Buying Opportunity - Benzinga
- 1 day ago - These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results - Benzinga
- 1 day ago - Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug - Investopedia
- 1 day ago - Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 2 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Vertex tops estimates on cystic fibrosis treatment strength, new products - Reuters
- 2 days ago - Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings - WSJ
- 2 days ago - Vertex to stop developing new painkiller as solo treatment after mid-stage study setback - Reuters